\
&
Contact us
\
&
Contact us
Published on | 6 months ago
Programmes Digital, Industry & Space AI Continent Deployment: Best use of technologiesThe European Commission has published guidelines on prohibited artificial intelligence (AI) practices, as defined by the EU AI Act. The guidelines provide an overview of AI practices that are considered unacceptable due to their potential risks to European values and fundamental rights.
The AI Act, which aims to promote innovation while ensuring high levels of health, safety, and fundamental rights protection, classifies AI systems into different risk categories, including prohibited, high-risk, and those subject to transparency obligations.The guidelines specifically address practices such as harmful manipulation, social scoring, and real-time remote biometric identification.
The guidelines aim to provide a consistent, effective and uniform application of the AI Act. They are non-binding, with authoritative interpretations reserved for the Court of Justice of the European Union (CJEU). The guidelines provide legal explanations and practical examples to help stakeholders understand and comply with the AI Act's requirements.
It is important to note that at this stage, the Commission has approved the draft guidelines, but not yet formally adopted them.
The guidelines can be found on the Commission website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The NIS Cooperation Group has launched a survey to collect feedback aimed at guiding the future steps towards implementing quantum-safe cryptography in Europe. This initiative follows the release of the "Coordinated Implementation Roadmap for the Transition to Post-Quantum Cryptography (PQC)". Quantum computing poses significant challenges to data... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
